Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Well-Being, Psychological
Interventions: mental health app; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Gastrointestinal Neoplasms
Interventions: Traction Device; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed/Refractory AML
Interventions: Universal donor derived CD33 CAR-NK; Biological
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Year to 39 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertensive Disorders of Pregnancy (HDP)
Interventions: Remote Blood Pressure Monitoring; Behavioral
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteer, Malaria
Interventions: 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan; Diagnostic Test
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 54 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Pre-exposure Prophylaxis
Interventions: Interview and survey to evaluate patient reported outcomes between the two medications.; Other
Lead sponsor: Anupama Raghuram MD; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Louisville, Kentucky

Conditions: Cardiac Anomalies
Interventions: AI Pocus_Cardiac; Diagnostic Test
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: 1 Month to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prediabetes
Interventions: FUERTE Arm, Standard care, No Intervention; Behavioral · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions: Observational Cohort (No Intervention); Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Atlanta, Georgia • Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab, LymphDetect assay, Surgery +/- neoadjuvant pembrolizumab; Drug · Radiation · Diagnostic Test + 1 more
Lead sponsor: Kevin Contrera; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gambling Disorder, Gambling Problem
Interventions: Contingency management, Cognitive behavioral therapy/ treatment as usual; Behavioral
Lead sponsor: East Tennessee State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Prostate Cancer, Metastatic Prostate Cancer
Interventions: Sipuleucel-T, N803; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes
Interventions: CHW-led T2D Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Psychosocial Functioning, Stress Disorders, Post-Traumatic, Depressive Disorder, Major
Interventions: Self-Guided STAIR Coach with Real-Time Assessment, Real-Time Assessment; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
Interventions: Empagliflozin 10 MG, Placebo Oral Tablet; Drug
Lead sponsor: Justin Ryder; Other
Eligibility: 12 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sepsis, Burn, Inflammation, Burn Infection
Interventions: PSP Monitoring; Device
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Multiple Myeloma, Heart Disease Risk Factors
Interventions: Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway; Other
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Laparoscopic Adnexal Surgery
Interventions: Normal Saline (0.9% NaCl), Marcaine hydrochloride without epinephrine 0.5%; Other · Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Metabolic Dysfunction-steatohepatitis (MASH)
Interventions: Not listed
Lead sponsor: Radnet Management, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Houston, Texas • Pearland, Texas

Conditions: Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy, Radiation Toxicity
Interventions: ORAL CARE PRODUCT KIT; Other
Lead sponsor: UNCANCER LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Heme Malignancy
Interventions: Progressive Muscle Relaxation delivered via Virtual Reality; Combination Product
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: HIV Prevention, Pre-Exposure Prophylaxis (PrEP)
Interventions: RAPID Response peer navigation, Emtricitabine/tenofovir disoproxil fumarate (F/TDF); Behavioral · Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hyperopia, Farsightedness, Hypermetropia
Interventions: Experimental treatment arm; Combination Product
Lead sponsor: Ohio State University; Other
Eligibility: 13 Weeks to 19 Weeks
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obesity & Overweight
Interventions: Tirzepatide, Exercise; Drug · Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Mental Health App and Impact on Wellbeing

Feasibility and Prospective Study of a Dynamic Traction Device for Use During ESD

Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML

Feasibility of Remote Blood Pressure Monitoring to Improve Management of Hypertensive Disorders of Pregnancy

Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection

Long-Acting Injectable HIV PrEP PROs

Prospective Evaluation of Cardiac Point-of-Care Ultrasound (POCUS) Performed by PEM Fellows and Artificial Intelligence on Children With Pre-existing Cardiac Conditions.

Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs

TDAP in Burn Patients (Group 2)

Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

Contingency Management to Reinforce Attendance to Cognitive Behavioral Treatment for Gambling Disorder

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

South Asians With Type 2 Diabetes at Risk for Depression

A Mobile Health Intervention to Improve Psychosocial Functioning in Veterans With Posttraumatic Stress Disorder and Depression Symptoms

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Sepsis Biomarker Monitoring in Burn Patients

MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma

Pain with Differing Intraperitoneal Washes At the End of Laparoscopic Gynecologic Surgery

Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy

Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy

Progressive Muscle Relaxation Delivered Via Virtual Reality - an Intervention for Patients Undergoing Cellular Therapy

Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator

The Emmetropization Via Accommodation (EVA) - II Study

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)